33 results about "Beta-cell Function" patented technology

The invention provides a stem cell exosome vesicle induced by traditional Chinese medicine functional components as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method of the stem cell exosome vesicle, traditional Chinese medicine functional components serve as an exosome inducer, stem cells can be induced to proliferate and secrete exosome with the enhanced function, the yield of the exosome can be increased, bioactive molecules can be loaded, and the bioavailability of the exosome in diabetes treatment is remarkably improved. The stem cell exosome vesicle disclosed by the invention can be applied to treatment of diabetes and complications thereof, not only can improve functions of islet cells, but also can treat chronic inflammation, microangiopathy and other metabolic diseases related to diabetes, and has a wide clinical application prospect.

The invention relates to a lactic acid bacterium capable of reducing fat, resisting inflammation and reducing blood sugar, which is classified and named as pediococcus acidilactici XJ335, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30093, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain can achieve the fat reducing effect by adjusting the abundance of intestinal flora; the levels of IL-6 and TNF-alpha in serum of diabetic mice are remarkably improved through regulation, so that the anti-inflammatory effect is achieved; various cardiovascular diseases of atherosclerosis are prevented by adjusting the levels of TC, TG, HDL-C and LDL-C; by reducing FINS and HOMA-IR levels and improving HOMA-IS, HOMA-beta and QUICKI value levels, insulin resistance of a body is reduced, insulin sensitivity and pancreas islet beta cell functions of the body are improved, gene expression related to blood sugar regulation is regulated, and an excellent blood sugar reducing effect is achieved in the body.

The invention relates to the technical field of biological medicines, in particular to application of N-acetyl serotonin in prevention and treatment of diabetes mellitus, and tests show that NAS has an obvious improvement effect on symptoms of weight loss, water intake increase and diet increase of T2DM mice; the NAS is used for improving the fasting blood glucose and the glucose tolerance level of the T2DM mouse; the NAS reduces the glycated serum protein and insulin resistance level of the T2DM mouse; the pancreatic beta cell function and insulin sensitivity of the T2DM mouse are improved. Therefore, the medicine N-acetyl serotonin has a good clinical application prospect in treating the type 2 diabetes mellitus and has important significance in developing a novel medicine composition for treating the type 2 diabetes mellitus.

The invention discloses a composite combined preparation for synergistically treating and conditioning diabetes, relates to the technical field of foods, health foods or dietary supplements for adjuvant therapy and health care of diabetes, and in particular relates to a composite combined preparation for synergistically treating and conditioning diabetes. The preparation comprises albumin peptide, saussurea involucrata culture, vitamin B1, vitamin B2, wheat oligopeptide, corn oligopeptide, collagen peptide, mulberry leaf extract, rhizoma polygonati extract, sea-buckthorn extract, isomaltitol, maltodextrin, ginseng extract and bitter gourd extract. Through the synergistic effect of all the components, comprehensive auxiliary conditioning on diabetes is realized from multiple targets of maintaining colloid osmotic pressure and nutrition, regulating glycolipid metabolism in multiple ways, protecting pancreatic beta cell functions, enhancing insulin sensitivity, preventing nerve and blood vessel complications, meeting special diet requirements and the like. The composition can be prepared into food, health-care food or dietary supplement and other dosage forms.

The invention relates to the technical field of functional reconstruction of functional beta cells of diabetic patients, in particular to a design method and device for functional reconstruction of beta cells based on single-cell multi-omics and a development potential energy field, and is suitable for accurate design and verification of a functional beta cell regeneration treatment scheme of the diabetic patients. According to the method and the device disclosed by the invention, efficient design and verification of a personalized beta cell function reconstruction scheme are realized by integrating single-cell multi-omics data, an embryonic development mechanism and an optimal control theory.

The invention relates to application of lactobacillus acidophilus LA85 in preparation of a product with a blood sugar reducing effect. The brand new application of the lactobacillus acidophilus LA85 strain is developed, namely the lactobacillus acidophilus LA85 strain is used for inhibiting alpha-glucosidase, reducing blood sugar and improving diabetes mellitus, and tests prove that the food intake, the water intake and the urine volume of a mouse with type II diabetes mellitus can be effectively controlled after intervention of the LA85 strain, and the weight value of the mouse is stabilized; the glucose absorption and metabolism capability of diabetic mice is effectively improved, and continuous damage of pancreatic beta cell functions is retarded; the blood lipid level disorder state of the mouse with the type II diabetes mellitus is improved; the inflammation level of a mouse body with type II diabetes mellitus is reduced, and the immunity is improved; and a very good improvement and recovery effect is achieved on abundance and diversity reduction of intestinal flora of the type II diabetes mellitus mice.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

The present invention discloses the application of Alternariol in the preparation of diabetes prevention and treatment drugs, which belongs to the field of medical technology. The present invention first screens out the compound Alternariol through in vitro DYRK1A kinase activity experiment, and its IC 50 The value was 20μM. Then, through INS-1 cell proliferation model experiments, it was found that the compound Alternariol can promote INS-1 cell proliferation and promote insulin secretion by pancreatic islet cells. Even at very low concentrations, such as 300nmol, it can significantly promote INS-1 cell proliferation. Finally, through mouse diabetes model experiments, it was further verified that the compound Alternariol can indeed control blood sugar in T1D mice and promote pancreatic proliferation in mice, while also having no toxic effects on the mouse body. This invention has extraordinary significance for T1B diabetes with impaired pancreatic cell function.

The invention discloses modified milk powder for old people for assisting in reducing blood sugar level and a preparation method of the modified milk powder. The modified milk powder comprises a milk-based composition, a hypoglycemic functional composition, a dietary fiber composition, a vitamin composition and a mineral composition. The composition with the hypoglycemic function is prepared from mulberry leaf extract, barley malt flour, white kidney bean powder, L-arabinose, lotus leaf powder, ginkgo powder and lactobacillus rhamnosus JYLR-005 and has the functions of regulating carbohydrate metabolism and improving pancreas islet beta-cells, animal experiment research proves that the composition can remarkably reduce fasting blood glucose of hyperglycemia model rats, and the blood glucose reducing effect is good. The modified milk powder provided by the invention has the advantages that the effect of assisting in reducing blood sugar can be realized by drinking the modified milk powder after half of medication, the reduction rate of fasting blood sugar value is 4.73-10.77%, and the reduction rate of blood sugar value after 1 hour after meal is 5.89-14.60%. The modified milk powder provided by the invention has the advantages that the effect of assisting in reducing blood sugar can be realized by taking the modified milk powder after half of medication. Compared with the total mixing time of the modified milk powder prepared by three-dimensional equipment, the total mixing time of the modified milk powder prepared by adopting a pneumatic mixing process is obviously shortened, the working efficiency is very effectively improved, and meanwhile, the personnel consumption is reduced. On the basis of meeting the nutritional requirements of consumers on dairy product intake, the modified milk powder has lower blood sugar load, is wider in intake crowd compared with conventional modified milk powder, and is more beneficial to old people suffering from obesity, hyperglycemia and the like; meanwhile, the preparation method is simple and efficient, and has a wide application prospect.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

This application provides an NPQ-IgG2 / Fc fusion protein and its applications. The fusion protein comprises an NPQ polypeptide and a human IgG2 / Fc region. The NPQ-IgG2 / Fc fusion protein has the ability to specifically bind to hepatocyte HEPG2 and insulin-secreting cells INS-1, and after binding to cells, it undergoes endocytosis, activating intracellular signaling pathways. This application also discloses that the NPQ-IgG2 / Fc fusion protein, through multi-target effects including promoting hepatocyte glucose and lipid metabolism and improving pancreatic β-cell function, can be used to treat liver diseases including fatty liver, diabetes, and other metabolic diseases related to glucose or lipid metabolism disorders.

This invention discloses a method for constructing a type 2 diabetes mouse model combining artificial intelligence prediction and multi-target knockout. The method involves acquiring and standardizing multi-omics data and baseline phenotypic data of mice to form a standardized modeling dataset; constructing an interaction map covering pancreatic β-cell function based on this data; selecting target target combinations and target phenotypic prediction results; generating construction instructions and submitting them to a controlled facility for multi-gene knockout modification to obtain modified mice and modification receipts; obtaining measured phenotypic data of the modified mice based on the modification receipts; comparing this data with the target phenotypic prediction results to generate phenotypic deviation metrics and phenotypic determination results; and registering the target target combinations, prediction results, measured phenotypic data, and modification receipts when the phenotypic determination results are satisfactory to form a type 2 diabetes composite mouse model. This invention achieves closed-loop optimization of AI-driven multi-target genetic modification, improving the efficiency and accuracy of constructing animal models of complex metabolic diseases.

The invention discloses a synthesis method of a fullerene nano material with glycolipid metabolism regulation capability, and belongs to the technical field of material science and biomedical engineering. The fullerene and the metformin are combined through chemical bonds, the strong oxidation resistance of the fullerene and the hypoglycemic effect of the metformin are exerted at the same time, the synergistic treatment effect is formed, and the drug composition is superior to a single drug; active oxygen in cells can be efficiently removed, oxidative stress is effectively relieved, and the functions of pancreatic beta cells are protected; through structural modification, the problem of low bioavailability caused by hydrophobicity of fullerene and hydrophilicity of metformin is solved, and the solubility and absorption efficiency of the medicine are improved; in conclusion, through chemical combination of the fullerene and the metformin, a dual-mechanism synergistic effect of oxidation resistance and blood sugar reduction is achieved, the treatment effect is remarkably improved, meanwhile, good safety and biocompatibility are achieved, and important application value is achieved in the field of treatment of the type II diabetes mellitus.

The invention discloses a type 2 diabetes mellitus mouse model construction method combining artificial intelligence prediction and multi-target knockout. Acquiring and standardizing mouse multi-omics data and phenotype baseline data to form a standardized modeling data set; constructing an interaction map covering the functions of the pancreatic beta cells on the basis of the data; screening to obtain a target combination and a target phenotype prediction result, generating a construction instruction, and submitting the construction instruction to a controlled facility to execute multi-gene knockout transformation, so as to obtain a transformed mouse and a transformation receipt; acquiring actual measurement phenotype data of the transformed mouse based on the transformation receipt, and comparing the actual measurement phenotype data with a target phenotype prediction result to generate phenotype deviation measurement and a phenotype judgment result; and when the phenotype determination result is satisfied, registering the target combination, the prediction result, the actually measured phenotype data and the transformation receipt to form the type-2 diabetes mellitus composite mouse model. According to the method, AI-driven multi-target genetic modification closed-loop optimization is realized, and the efficiency and accuracy of complex metabolic disease animal model construction are improved.

The invention discloses a stem cell medicine for pancreas islet repair and application, and belongs to the technical field of stem cell biology, and the stem cell medicine for pancreas islet repair is prepared by compounding a carrier, pancreatic progenitor cells and pancreas islet-like cells in proportion. The problems that in the prior art, due to the fact that stem cells are unstable in differentiation efficiency, poor in synergistic effect and poor in biocompatibility, islet injury cannot be repaired, and diabetes cannot be treated are solved. According to the present invention, the dual mechanisms of endogenous beta cell repair and exogenous beta cell supplement are adopted, and the beta cell function recovery and the group structure reconstruction are synchronously achieved through the reasonable ratio, such that the in-vivo blood glucose of the mouse is significantly reduced, the beta cell number and the glucose tolerance dose of the mouse are increased, and the low immunogenicity and the high anti-inflammatory property are simultaneously provided. The compound can be used for treating type I and type II diabetes mellitus, improving the insulin secretion function and relieving local inflammatory response of pancreas by promoting pancreas islet beta cell proliferation, and has application potential in treatment of type I and type II diabetes mellitus and pancreas islet repair.

The invention belongs to the technical field of biological medicine, and provides a human umbilical cord mesenchymal stem cell preparation and application thereof, the preparation comprises human umbilical cord mesenchymal stem cells, ginsenoside Rg3 and a medicinal carrier; the medicinal carrier is a phosphate buffer solution; according to the application, 1 * 10 < 6 > HUCMSCs pretreated by Rg3 are subjected to caudal vein injection on a T2DM mouse model induced by high fat diet combined with STZ, the curative effect and mechanism are verified by combining OGTT, IPITT, serum biochemical detection, HE / PAS tissue staining, q-PCR and other technologies, and finally the purposes of improving glycometabolism of the T2DM mouse, repairing liver / kidney / pancreas target organ injuries, protecting pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions, reducing pancreas islet beta cell functions and the like are achieved. And a theoretical basis is provided for accurate intervention of T2DM by activating an IGF-1R / PI3K-AKT signal channel and regulating and controlling the expression of a glycometabolism-related gene.

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The invention relates to the field of biological medicines, in particular to application of a hepatocyte nuclear factor 1 alpha (HNF1 alpha) in promoting beta cell regeneration and preventing and treating diabetes. Specifically, by regulating and controlling the expression of an HNF1alpha coding gene and the activity of HNF1alpha, pancreas islet alpha cells can be promoted to be transdifferentiated into beta cells to achieve beta cell regeneration, the functions of pancreas islet beta cells are reserved, the occurrence of diabetes mellitus is delayed, and a new medical approach is provided for prevention and treatment of diabetes mellitus.

The invention discloses an application of a jerusalem artichoke tuber alcohol extract in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the technical field of medicines, the chemical components of the jerusalem artichoke tuber alcohol extract are mainly flavonoid substances, and the jerusalem artichoke tuber alcohol extract can remarkably recover the weight of a mouse with the type 2 diabetes mellitus and improve glucose metabolism indexes such as fasting blood-glucose and oral glucose tolerance; meanwhile, insulin sensitivity is stimulated to secrete insulin, and the functions of pancreatic beta cells are recovered; in addition, the concentration of biochemical indexes such as total cholesterol and triglyceride in the liver is reduced, lipid metabolism of the liver is improved, and a new direction is provided for research and development of natural plant source hypoglycemic products.

The present application provides a traditional Chinese medicine composition with blood sugar lowering efficacy and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines; the traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: birch juice 140-200 parts, jujube fruit 20-40 parts, rehmannia 20-40 parts, adenosma 18-26 parts, periploca 18-26 parts, ophiopogon 18-26 parts, bamboo shavings 12-19 parts, leech 12-19 parts, psyllium 12-19 parts, dogwood 10-14 parts, gordon euryale seed 10-14 parts. In the traditional Chinese medicine composition, the blood sugar lowering effect is mainly achieved by repairing the function of islet beta cells, promoting the regeneration of islet beta cells, improving sugar metabolism, increasing the sensitivity of insulin or improving insulin resistance, so that the overall prescription achieves the effects of invigorating the spleen and lung, nourishing yin and reducing fire, benefiting the stomach and producing saliva, astringing the spleen essence, promoting transportation and transformation, tonifying the kidney and strengthening the body, and relieving polydipsia and restlessness.

The invention discloses a fusion protein for regulating and controlling functions of pancreatic beta cells based on an optogenetics technology and application of the fusion protein, and relates to the technical field of biology. The fusion protein Opto LOVTRAP disclosed by the invention has very high temporal-spatial resolution, and rapid and accurate control on a single cell can be realized by adjusting blue light; opto LOVTRAP has reversibility, can effectively inhibit a pancreatic beta cell Ca < 2 + > channel under a dark condition, and can quickly stop playing a role after being stimulated by blue light, so that the purpose of reversibly and accurately regulating insulin secretion is achieved. Opto LOVTRAP is targeted to regulate the concentration of Ca < 2 + > in cells, and is a final triggering factor for release of pancreas islet vesicles, so that the opto LOVTRAP is not influenced by the KATP function, and the purpose of breaking through the bottleneck of a traditional clinical treatment mode is achieved.

The application provides application of ceramide hydrolase ACER2 in preparation of a medicine for improving beta cell function, preventing and / or treating diabetes. The application proves, for the first time, through a pancreatic islet beta cell damage regeneration model and a diabetes mouse model, that ACER2 is indispensable for regulating ceramide level, improving beta cell function and diabetes pathological phenotype by specifically knocking out a metabolic enzyme ACER2 of vascular endothelial cells; and constructs extracellular vesicles overexpressing ACER2, and proves that the extracellular vesicles overexpressing ACER2 have certain application prospect in improvement of pancreatic islet beta cell function and treatment of diabetes.

Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into the mature beta cells of enriched beta clusters, wherein the beta cells rapidly and reliably secrete insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals. These cells can also be used for drug screening purposes to identify factors / chemicals capable of increasing beta cell functions, proliferation, survival, and resistance to immune assault.

Type 1 diabetes (T 1 D) is caused by the autoimmune destruction of insulin producing beta cells in the islets of Langerhans leading to dependence on exogeneous insulin injections for survival. A need exists for a treatment that would prevent or delay the onset of clinical T1 D in high-risk individuals. One promising therapy is the anti-CD3 monoclonal antibody teplizumab, as several studies have shown that short-term treatment reduces loss of beta cell function durably, with an observable effect seen as long as 7 years after diagnosis and treatment. Furthermore, improved methods for prognosing such prevention or delay are also needed. Provided herein, in one aspect, is a method of prognosing responsiveness of an anti-CD3 antibody in preventing or delaying the onset of T1 D.

The present disclosure is directed to isolated cell populations comprising a T cell receptor that targets proinsulin and regulatory T cells that exogenously express the T cell receptor for use in treating type 1 diabetes. In some aspects, provided herein is an autologous T cell (e.g., regulatory T cell) therapy for the treatment of type 1 diabetes (T1D), e.g., the treatment of T1D in patients with the HLA-DRB1*04:01 genetic haplotype. In some embodiments, the therapy is a targeted therapy for T1D patients who have residual / residual beta cell function in the pancreas (e.g., still produce insulin).

Methods are provided for the simple, fast, effective and safe directed differentiation of embryonic stem cells into the mature beta cells of enriched beta clusters, wherein the beta cells rapidly and reliably secrete insulin in response to glucose levels. The cells are useful transplant therapeutics for diabetic individuals. These cells can also be used for drug screening purposes to identify factors / chemicals capable of increasing beta cell functions, proliferation, survival, and resistance to immune assault.

The application relates to the technical field of stem cell engineering and regenerative medicine, and specifically discloses a stem cell treatment method for treating type 2 diabetes. The method comprises the following steps: S1, extracting placenta-derived mesenchymal stem cells; S2, performing multi-gene modification on the mesenchymal stem cells to obtain gene-modified mesenchymal stem cells; S3, pretreating the gene-modified mesenchymal stem cells with a culture medium; S4, extracting microvesicles from the mesenchymal stem cells; S5, mixing the microvesicles, baicalin, L-arginine and vitamin D in a buffer to form a composite preparation; S6, introducing the composite preparation into a patient's body through abdominal cavity intervention; and S7, performing synergistic treatment by combining oral administration of an SGLT2 inhibitor after infusion, and regularly monitoring islet function indexes. The stem cell treatment method can be used for treating type 2 diabetes, and has the advantages of being targeted to improve the islet microenvironment, promoting the recovery of beta cell function and being durable in action.

The present application relates to the technical field of biological medicine and gene therapy, and particularly relates to a nucleic acid delivery system targeting pancreatic beta cells and application thereof. The nucleic acid delivery system comprises a nanocomplex formed by a cationic polymer modified with a targeting ligand and siRNA; the targeting ligand is a GLP-1 receptor targeting peptide; the cationic polymer is a PEI-PFA polymer; and the siRNA is siRNA targeting DYRK1A. The present application provides a novel pancreatic beta cell targeting delivery platform for gene therapy of type 2 diabetes. The platform realizes beta cell function regeneration by precisely regulating DYRK1A gene expression, and has targeting, safety and high efficiency, thereby providing a new strategy with broad clinical application prospect for diabetes treatment.

The invention discloses a mesenchymal stem cell for treating type 2 diabetes mellitus, a preparation method and application. Belongs to the technical field of biology. The method comprises the following steps: firstly, separating mesenchymal stem cells from umbilical cord tissues, and then efficiently transducing a lentiviral vector carrying a Glymaxylin gene into the cells by adopting an optimized centrifugal enhancement method. The transduction process is carried out under a specific transduction enhancer, the infection complex number and the cell fusion degree are accurately controlled, and then centrifugation is carried out to greatly improve the transduction efficiency. And screening the transduced cells, and amplifying the cells in a serum-free culture medium added with bFGF (basic fibroblast growth factor) and / or EGF (epidermal growth factor), so as to finally obtain the high-activity and high-expression Glymaxylin gene mesenchymal stem cell for treatment. By systematically optimizing the preparation process, the problem of unstable transduction efficiency is solved, and the prepared cell product can effectively promote the functional recovery of the pancreatic beta cells and lays a solid foundation for developing cell drugs.

The present invention belongs to the field of carrier / medical technology for treating metabolic diseases, and specifically relates to responsive prebiotics-mimicking hydrogen production nanoparticles and their applications. The present invention constructs a plant exosome bionic oral nanoformulation HMS / A@GE, which fully combines the advantages of exosomes from edible prebiotics and mesoporous silica carriers, overcomes the limitations of existing microecological therapies, realizes the combination of microecological therapy and antioxidant therapy, and synergistically exerts the effects of lowering blood sugar and reducing fat, providing a safe, economical and controllable strategy for treating diabetes based on regulating intestinal microecology. The HMS / A@GE of the present invention improves the intestinal Lactobacillus spp. It can promote the release of GLP-1 from intestinal L cells and activate intestinal AhR receptors, promote the release of IL-22, improve insulin resistance and pancreatic β-cell function, and ultimately play a role in lowering blood sugar and reducing fat.